ATE496051T1 - Pyrazolotetrahydropyridinderivate als orexinrezeptorantagonisten - Google Patents

Pyrazolotetrahydropyridinderivate als orexinrezeptorantagonisten

Info

Publication number
ATE496051T1
ATE496051T1 AT07735643T AT07735643T ATE496051T1 AT E496051 T1 ATE496051 T1 AT E496051T1 AT 07735643 T AT07735643 T AT 07735643T AT 07735643 T AT07735643 T AT 07735643T AT E496051 T1 ATE496051 T1 AT E496051T1
Authority
AT
Austria
Prior art keywords
receptor antagonists
pyrazolotetrahydropyridine
derivatives
orexin receptor
orexin
Prior art date
Application number
AT07735643T
Other languages
English (en)
Inventor
Hamed Aissaoui
Christoph Boss
Markus Gude
Ralf Koberstein
Thierry Sifferlen
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Application granted granted Critical
Publication of ATE496051T1 publication Critical patent/ATE496051T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
AT07735643T 2006-04-26 2007-04-25 Pyrazolotetrahydropyridinderivate als orexinrezeptorantagonisten ATE496051T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2006051300 2006-04-26
PCT/IB2007/051522 WO2007122591A2 (en) 2006-04-26 2007-04-25 Pyrazolo-tetrahydro pyridine derivatives as orexin receptor antagonists

Publications (1)

Publication Number Publication Date
ATE496051T1 true ATE496051T1 (de) 2011-02-15

Family

ID=38541955

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07735643T ATE496051T1 (de) 2006-04-26 2007-04-25 Pyrazolotetrahydropyridinderivate als orexinrezeptorantagonisten

Country Status (8)

Country Link
US (1) US7834028B2 (de)
EP (1) EP2013209B1 (de)
JP (1) JP2009535324A (de)
CN (1) CN101432285A (de)
AT (1) ATE496051T1 (de)
CA (1) CA2647077A1 (de)
DE (1) DE602007012072D1 (de)
WO (1) WO2007122591A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2378257C2 (ru) 2004-03-01 2010-01-10 Актелион Фармасьютиклз Лтд Замещенные производные 1,2,3,4-тетрагидроизохинолина
ATE458740T1 (de) * 2006-08-28 2010-03-15 Actelion Pharmaceuticals Ltd 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen- derivate als orexinrezeptor-antagonisten
AU2007337659A1 (en) 2006-12-22 2008-07-03 Actelion Pharmaceuticals Ltd. 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives
CA2681163A1 (en) 2007-04-04 2008-10-16 F. Hoffmann-La Roche Ag Heterocycles as orexin antagonists
HRP20120240T1 (hr) 2007-05-23 2012-04-30 Merck Sharp & Dohme Corp. Piridil piperidin antagonisti receptora za oreksin
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009083903A1 (en) 2007-12-28 2009-07-09 Actelion Pharmaceuticals Ltd Trisubstituted 3,4-dihydro-1h-isoquinolin compound, process for its preparation, and its use
CN101918361B (zh) * 2008-02-12 2014-05-28 弗·哈夫曼-拉罗切有限公司 哌啶磺酰胺衍生物
AU2009215243A1 (en) * 2008-02-21 2009-08-27 Actelion Pharmaceuticals Ltd. 2-aza-bicyclo[2.2.1]heptane derivatives
ME03452B (de) 2009-10-23 2020-01-20 Janssen Pharmaceutica Nv Disubstituierte octahy-dropyrrolo [3,4-c]pyrrole als orexinrezeptormodulatoren
ES2460915T3 (es) * 2009-12-21 2014-05-16 Novartis Ag Piridinas fusionadas con heteroarilo disustituido
WO2012114252A1 (en) 2011-02-21 2012-08-30 Actelion Pharmaceuticals Ltd Novel indole and pyrrolopyridine amides
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2508511A1 (de) * 2011-04-07 2012-10-10 Laboratoire Biodim Inhibitoren der Virenreplikation, Verfahren zu deren Herstellung und deren therapeutische Verwendung
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
JP6346862B2 (ja) 2012-02-07 2018-06-20 エオラス セラピューティクス， インコーポレイテッド オレキシンレセプターアンタゴニストとしての置換プロリン／ピペリジン
GB201308236D0 (en) * 2013-05-08 2013-06-12 Givaudan Sa Improvements in or relating to organic compounds
WO2014205782A1 (en) 2013-06-28 2014-12-31 Givaudan Sa Organic compounds
TW201613902A (en) 2014-08-13 2016-04-16 Eolas Therapeutics Inc Difluoropyrrolidines as orexin receptor modulators
WO2016074698A1 (en) 2014-11-10 2016-05-19 Givaudan Sa Improvements in or relating to organic compounds
WO2016074696A1 (en) * 2014-11-10 2016-05-19 Givaudan Ag Perfume ingredients and perfume preparations containing same
US10894789B2 (en) 2016-02-12 2021-01-19 Astrazeneca Ab Halo-substituted piperidines as orexin receptor modulators
KR20230116948A (ko) 2016-03-10 2023-08-04 얀센 파마슈티카 엔.브이. 오렉신-2 수용체 길항제를 사용한 우울증의 치료 방법
EP3454857A1 (de) 2016-05-10 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und pharmazeutische zusammensetzungen zur behandlung entzündlicher augenkrankheiten
CN111494376A (zh) * 2020-06-15 2020-08-07 牡丹江医学院 一种用于治疗牙龈炎的药物及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2234840T3 (es) 2000-03-14 2005-07-01 Actelion Pharmaceuticals Ltd. Derivados de 1,2,3,4- tetrahidroisoquinolina.
WO2001085693A1 (en) 2000-05-11 2001-11-15 Banyu Pharmaceutical Co., Ltd. N-acyltetrahydroisoquinoline derivatives
WO2002051232A2 (en) 2000-12-27 2002-07-04 Actelion Pharmaceuticals Ltd. Novel benzazepines and related heterocyclic derivatives
PT1501804E (pt) 2002-04-26 2009-10-29 Hoffmann La Roche Derivados de isoquinolina
US6709392B1 (en) * 2002-10-10 2004-03-23 Koninklijke Philips Electronics N.V. Imaging ultrasound transducer temperature control system and method using feedback
RU2345985C2 (ru) 2003-03-26 2009-02-10 Актелион Фармасьютиклз Лтд. Производные тетрагидроизохинолилацетамида в качестве антагонистов орексинового рецептора
RU2378257C2 (ru) * 2004-03-01 2010-01-10 Актелион Фармасьютиклз Лтд Замещенные производные 1,2,3,4-тетрагидроизохинолина
FR2874011B1 (fr) 2004-08-03 2007-06-15 Sanofi Synthelabo Derives de sulfonamides, leur preparation et leur application en therapeutique
EA015256B1 (ru) 2006-03-15 2011-06-30 Актелион Фармасьютикалз Лтд. Производные тетрагидроизохинолина для повышения функции памяти

Also Published As

Publication number Publication date
WO2007122591A2 (en) 2007-11-01
JP2009535324A (ja) 2009-10-01
EP2013209B1 (de) 2011-01-19
US7834028B2 (en) 2010-11-16
DE602007012072D1 (de) 2011-03-03
EP2013209A2 (de) 2009-01-14
US20090099228A1 (en) 2009-04-16
CA2647077A1 (en) 2007-11-01
WO2007122591A3 (en) 2008-01-10
CN101432285A (zh) 2009-05-13

Similar Documents

Publication Publication Date Title
DE602007012072D1 (de) Orantagonisten
ATE500250T1 (de) Azetidinverbindungen als orexin-rezeptor- antagonisten
ATE505467T1 (de) 2-aza-bicycloä3.1.0ühexanderivate als orexin- rezeptorantagonisten
ATE458740T1 (de) 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen- derivate als orexinrezeptor-antagonisten
ATE481405T1 (de) Thiazolpyrazolopyrimidine als antagonisten des crf1-rezeptors
EP2348846A4 (de) Disubstituierte azepanorexin-rezeptorantagonisten
ATE524466T1 (de) 3-azabicycloä3.3.0üoktanverbindungen
DK2089382T3 (da) Substituerede diazepan-forbindelser som orexin-receptor-antagonister
EA201170884A1 (ru) Производные пиперидина, пригодные в качестве антагонистов орексина
ATE469895T1 (de) Cgrp-rezeptorantagonisten
EA200870409A1 (ru) Антагонисты киназы pi3
HRP20151108T1 (xx) Antagonisti nogo-receptora
EP2131654A4 (de) Bipyridin-carboxamid-orexin-rezeptorantagonisten
ATE509928T1 (de) 8-azabicycloä3.2.1üoktan-verbindungen als mu- opioid-rezeptorantagonisten
ATE555111T1 (de) Chinuclidinol-derivate als muscarinrezeptor- antagonisten
BRPI0817835A2 (pt) Antagonistas cgrp
EP2254413A4 (de) Imidazobenzazepin-cgrp-rezeptorantagonisten
ATE506343T1 (de) Malonamide als orexin-antagonisten
EP2170064A4 (de) 6,5-pyrrolopiperidin-tachykinin-rezeptorantagonisten
BRPI0814772A2 (pt) Indazóis substituídos por 5-piridinona
ATE533744T1 (de) N-benzoypyrrolidin-3-ylamine als histamin-3 antagonisten
ATE477243T1 (de) 2-aminochinoline als 5-ht(5a)- rezeptorantagonisten
ATE421511T1 (de) Indol-3-carbonyl-spiro-piperidinderivate als antagonisten des v1a-rezeptors
ATE547407T1 (de) Alkylthiopyrimidine als crth2-antagonisten
DK1973886T3 (da) Prokineticin-1-receptor-antagonister

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties